Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 4/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthurenate SCHEMBL379760 | 0.85 | KDM4E (0.59) | KDM4ETDP1MAPTRAB9AKMT2A | |
| Xanthurenate SCHEMBL29394132 | 0.85 | KDM4E (0.59) | KDM4ETDP1MAPTRAB9AKMT2A | |
| Xanthurenate SCHEMBL29911018 | 0.85 | KDM4E (0.59) | KDM4ETDP1MAPTRAB9AKMT2A | |
| SCHEMBL2807297 | 0.84 | KDM4E (0.60) | KDM4ETDP1MAPTRAB9ALMNA | |
| SCHEMBL1401134 | 0.83 | MAPT (0.45) | KDM4EMAPTLMNAKMT2AHPGD | |
| SCHEMBL20606488 | 0.81 | CYP1A2 (0.54) | KDM4ETDP1MAPTKMT2AGAA | |
| SCHEMBL6594758 | 0.81 | KDM4E (0.46) | KDM4ETDP1MAPTRAB9AKMT2A | |
| SCHEMBL3333164 | 0.81 | GRM2 (0.48) | KDM4ETDP1MAPTRAB9AKMT2A | |
| SCHEMBL6080058 | 0.81 | KDM4E (0.46) | KDM4ETDP1MAPTRAB9AKMT2A | |
| SCHEMBL6080750 | 0.81 | KDM4E (0.46) | KDM4ETDP1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578423-B1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7176207-B2 | Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7084142-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20060122188-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | US | disclosed |
| US-7056923-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-06 | — | — | US | disclosed |
| US-7026323-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | disclosed |
| EP-1633737-A1 | QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-15 | — | — | EP | disclosed |
| CN-1747732-A | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists | SCHERING AG (DE) | 2006-03-15 | — | — | CN | disclosed |
| US-6995156-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-02-07 | — | — | US | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-6861424-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20050020605-A1 | Quinolyl amide derivatives as CCR-5 antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004113323-A1 | QUINOLYL AMIDE DERIVATIVES AS CCR-5 ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-12-29 | — | — | WO | disclosed |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052366-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | WO | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020605-A1 | Quinolyl amide derivatives as CCR-5 antagonists | CCRL2, CCR5, CCR1 | KDM4E 2423/4885TDP1 4744/4885MAPT 3691/4885 |
| US-20060122188-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, P2RY1, ADORA1 | KDM4E 4082/4885TDP1 1982/4885MAPT 4866/4885 |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | KDM4E 4333/4885TDP1 1671/4885MAPT 4857/4885 |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | KDM4E 4333/4885TDP1 1671/4885MAPT 4857/4885 |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, ADORA1, P2RY1 | KDM4E 4372/4885TDP1 1534/4885MAPT 4869/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | KDM4E 4378/4885TDP1 1481/4885MAPT 4867/4885 |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, ADORA2B, TBXA2R | KDM4E 4296/4885TDP1 1766/4885MAPT 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.